This study investigated real-world edoxaban concentrations across different dosing regimens, with a specific focus on patients who met the inclusion criteria of low-dose edoxaban for the Elder Care Atrial Fibrillation (ELDERCARE-AF) trial. Patients with atrial fibrillation receiving edoxaban were enrolled to measure trough concentrations. The levels were compared with the expected therapeutic range (12–43 ng/mL) to… Continue reading Real-World #Edoxaban Concentrations in #Older Patients Receiving Reduced-Dose Regimens
Tag: DOAC
#Dementia Risk of Direct Oral Anticoagulants Versus Warfarin for Atrial #Fibrillation: Systematic Review and Meta-Analysis
BackgroundDirect-acting oral anticoagulants (DOACs) have demonstrated superior efficacy in preventing stroke and death compared with warfarin in patients with atrial fibrillation (AF), but their influence on dementia risk remains unclear.ObjectivesThe purpose of this study was to evaluate the relative risks of dementia in DOAC vs warfarin in patients with AF.MethodsAn electronic literature search was conducted… Continue reading #Dementia Risk of Direct Oral Anticoagulants Versus Warfarin for Atrial #Fibrillation: Systematic Review and Meta-Analysis
Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis
AbstractObjective: There has been limited systematic evaluation of outcomes and drivers of inappropriate non-vitamin K antagonist oral anticoagulants (NOACs) dosing among patients with atrial fibrillation (AF). This review identified and systematically evaluated literature on clinical and economic outcomes of inappropriate NOAC dosing and associated patient characteristics.Methods: MEDLINE, Embase, Cochrane Library, International Pharmaceutical Abstracts, Econlit, PubMed and NHS… Continue reading Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis
Managing bleeding risk after cold snare polypectomy in patients receiving direct-acting oral anticoagulants
Background and AimsThe best strategy to manage direct-acting oral anticoagulants (DOACs) for patients undergoing cold snare polypectomy remains unclear. This study compared the effect of continuing versus stopping DOACs only on the day of the procedure on bleeding after cold snare polypectomy. MethodsThis prospective, observational, single-center cohort study enrolled consecutive patients receiving antithrombotic agents and… Continue reading Managing bleeding risk after cold snare polypectomy in patients receiving direct-acting oral anticoagulants
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial
Patients hospitalised with COVID-19 are at risk for thrombotic events after discharge; the role of extended thromboprophylaxis in this population is unknown. MethodsIn this open-label, multicentre, randomised trial conducted at 14 centres in Brazil, patients hospitalised with COVID-19 at increased risk for venous thromboembolism (International Medical Prevention Registry on Venous Thromboembolism [IMPROVE] venous thromboembolism [VTE]… Continue reading Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial
#Edoxaban versus Vitamin K Antagonist for Atrial #Fibrillation after #TAVR
The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been well studied. METHODSWe conducted a multicenter, prospective, randomized, open-label, adjudicator-masked trial comparing edoxaban with vitamin K antagonists in patients with prevalent or incident atrial fibrillation as the indication for oral anticoagulation… Continue reading #Edoxaban versus Vitamin K Antagonist for Atrial #Fibrillation after #TAVR
Effectiveness and Safety of Direct Oral #Anticoagulants Versus Warfarin in Patients With Valvular Atrial #Fibrillation
Direct oral anticoagulants (DOACs) are increasingly used in place of warfarin, but evidence about their effectiveness and safety in patients with valvular atrial fibrillation (AF) remains limited. Objective: To assess the effectiveness and safety of DOACs compared with warfarin in patients with valvular AF. Design: New-user retrospective propensity score–matched cohort study. Setting: U.S.-based commercial health… Continue reading Effectiveness and Safety of Direct Oral #Anticoagulants Versus Warfarin in Patients With Valvular Atrial #Fibrillation
American Society of Hematology 2021 guidelines for management of venous #thromboembolism: prevention and treatment in patients with #cancer
Venous thromboembolism (VTE) is a common complication among patients with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and mortality. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and… Continue reading American Society of Hematology 2021 guidelines for management of venous #thromboembolism: prevention and treatment in patients with #cancer
#Endoscopy-related #bleeding and thromboembolic events in patients on direct oral anticoagulants or vitamin K antagonists
Few prospective studies have assessed the safety of direct oral anticoagulants (DOACs) in elective endoscopy. Our primary aim was to compare the risks of endoscopy-related gastrointestinal bleeding and thromboembolic events in patients on DOACs or vitamin K antagonists (VKAs) in this setting. Secondarily, we examined the impact of the timing of anticoagulant resumption on the… Continue reading #Endoscopy-related #bleeding and thromboembolic events in patients on direct oral anticoagulants or vitamin K antagonists
2 Medical News 